PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors

Francesco Dituri, Antonio Mazzocca, Gianluigi Giannelli, Salvatore Antonaci

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The immunological surveillance of tumors relies on a specific recognition of cancer cells and their associate antigens by leucocytes of innate and adaptive immune responses. However, a dysregulated cytokine release can lead to, or be associated with, a failure in cell-cell recognition, thus, allowing cancer cells to evade the killing system. The phosphatidylinositol 3-kinase (PI3K) pathway regulates multiple cellular processes which underlie immune responses against pathogens or malignant cells. Conversely, there is accumulating evidence that the PI3K pathway is involved in the development of several malignant traits of cancer cells as well as their escape from immunity. Herein, we review the counteracting roles of PI3K not only in antitumor immune response but also in the mechanisms that cancer cells use to avoid leukocyte attack. In addition, we discuss, from antitumor immunological point of view, the potential benefits and disadvantages arising from use of anticancer pharmacological agents targeting the PI3K pathway.

Original languageEnglish
Article number947858
JournalClinical and Developmental Immunology
Volume2011
DOIs
Publication statusPublished - 2011

Fingerprint

Phosphatidylinositol 3-Kinase
Tumor Escape
Immunity
Neoplasms
Immunologic Surveillance
Adaptive Immunity
HLA Antigens
Innate Immunity
Antineoplastic Agents
Leukocytes
Pharmacology
Cytokines

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)
  • Immunology and Allergy

Cite this

PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. / Dituri, Francesco; Mazzocca, Antonio; Giannelli, Gianluigi; Antonaci, Salvatore.

In: Clinical and Developmental Immunology, Vol. 2011, 947858, 2011.

Research output: Contribution to journalArticle

Dituri, Francesco ; Mazzocca, Antonio ; Giannelli, Gianluigi ; Antonaci, Salvatore. / PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. In: Clinical and Developmental Immunology. 2011 ; Vol. 2011.
@article{fd06835f2f5348c0921bc0ae085e8b6e,
title = "PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors",
abstract = "The immunological surveillance of tumors relies on a specific recognition of cancer cells and their associate antigens by leucocytes of innate and adaptive immune responses. However, a dysregulated cytokine release can lead to, or be associated with, a failure in cell-cell recognition, thus, allowing cancer cells to evade the killing system. The phosphatidylinositol 3-kinase (PI3K) pathway regulates multiple cellular processes which underlie immune responses against pathogens or malignant cells. Conversely, there is accumulating evidence that the PI3K pathway is involved in the development of several malignant traits of cancer cells as well as their escape from immunity. Herein, we review the counteracting roles of PI3K not only in antitumor immune response but also in the mechanisms that cancer cells use to avoid leukocyte attack. In addition, we discuss, from antitumor immunological point of view, the potential benefits and disadvantages arising from use of anticancer pharmacological agents targeting the PI3K pathway.",
author = "Francesco Dituri and Antonio Mazzocca and Gianluigi Giannelli and Salvatore Antonaci",
year = "2011",
doi = "10.1155/2011/947858",
language = "English",
volume = "2011",
journal = "Clinical and Developmental Immunology",
issn = "1740-2522",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors

AU - Dituri, Francesco

AU - Mazzocca, Antonio

AU - Giannelli, Gianluigi

AU - Antonaci, Salvatore

PY - 2011

Y1 - 2011

N2 - The immunological surveillance of tumors relies on a specific recognition of cancer cells and their associate antigens by leucocytes of innate and adaptive immune responses. However, a dysregulated cytokine release can lead to, or be associated with, a failure in cell-cell recognition, thus, allowing cancer cells to evade the killing system. The phosphatidylinositol 3-kinase (PI3K) pathway regulates multiple cellular processes which underlie immune responses against pathogens or malignant cells. Conversely, there is accumulating evidence that the PI3K pathway is involved in the development of several malignant traits of cancer cells as well as their escape from immunity. Herein, we review the counteracting roles of PI3K not only in antitumor immune response but also in the mechanisms that cancer cells use to avoid leukocyte attack. In addition, we discuss, from antitumor immunological point of view, the potential benefits and disadvantages arising from use of anticancer pharmacological agents targeting the PI3K pathway.

AB - The immunological surveillance of tumors relies on a specific recognition of cancer cells and their associate antigens by leucocytes of innate and adaptive immune responses. However, a dysregulated cytokine release can lead to, or be associated with, a failure in cell-cell recognition, thus, allowing cancer cells to evade the killing system. The phosphatidylinositol 3-kinase (PI3K) pathway regulates multiple cellular processes which underlie immune responses against pathogens or malignant cells. Conversely, there is accumulating evidence that the PI3K pathway is involved in the development of several malignant traits of cancer cells as well as their escape from immunity. Herein, we review the counteracting roles of PI3K not only in antitumor immune response but also in the mechanisms that cancer cells use to avoid leukocyte attack. In addition, we discuss, from antitumor immunological point of view, the potential benefits and disadvantages arising from use of anticancer pharmacological agents targeting the PI3K pathway.

UR - http://www.scopus.com/inward/record.url?scp=84855171780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855171780&partnerID=8YFLogxK

U2 - 10.1155/2011/947858

DO - 10.1155/2011/947858

M3 - Article

C2 - 22046194

AN - SCOPUS:84855171780

VL - 2011

JO - Clinical and Developmental Immunology

JF - Clinical and Developmental Immunology

SN - 1740-2522

M1 - 947858

ER -